Lumen Bioscience
Business Services · Washington, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
1441 N 34th St Ste 300, Seattle, Washing...Phone Number
(206) 899-1904Website
lumen.bioRevenue
$22 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
3
1
1
About Lumen Bioscience
Seattle-based Lumen Bioscience, Inc. has developed a new spirulina-based drug discovery, manufacturing, and delivery platform for highly prevalent diseases and disorders that have been difficult to address with conventional biopharmaceutical tools. Lumen's unique platform offers the potential to transform the biologics industry through increased speed, straightforward assembly of cocktail therapeutics, mass-market scale, and exponentially lower costs than legacy approaches. Lumen is advancing investigational oral biologic drugs and dietary supplements designed to act locally in the gut, with a pipeline targeting weight loss, C. difficile infection, inflammatory bowel disease, kidney stone disease, traveler's diarrhea, and other high prevalence conditions.Explore more
Lumen Bioscience Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Lumen Bioscience your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Lumen Bioscience is spiking on competitors!
Lumen Bioscience, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Lumen Bioscience has new funding data
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Lumen Bioscience recently announced quarterly report
Click to see if Lumen Bioscience had a recent Job posting/layoffs
Check if Lumen Bioscience has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Lumen Bioscience
Product Launch: Get notified when Lumen Bioscience launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Lumen Bioscience
Compare insights from companies similar to Lumen Bioscience, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Lumen Bioscience is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Lumen Bioscience is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Lumen Bioscience.
Lumen Bioscience financials insights
Gather financial insights about Lumen Bioscience, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Series A
$13M
2020
Debt
$350K
Series B
$16M
2025
Series C
$30M
Lumen Bioscience Tech Stack
A closer look at the technologies used by Lumen Bioscience
See more technologies
Most Recent Scoops
Person-Based
Events
Person-Based
Executive Move
Executive Moves, Board of Directors
Funding
Funding
Project
HRIS, Enterprise Software, Recruitment, Software, HR Operations, Talent Acquisition, Talent Management
Lumen Bioscience News & Media
Lumen Bioscience's LMN-201 Achieves 100% Initial C. difficile Clinical Cure in Preliminary Cohort of RePreve Trial
— Strong potential to disrupt market for treatment of C. diff infections — RePreve Trial main cohort now recruiting SEATTLE, April 3, 2025 /PRNewswire/ -- In a landmark achievement for its pioneering spirulina-based drug development platform, Lumen announced today top-line results from...Lumen Bioscience awarded $16.2 million in DoD funding to advance LMN-201 through late-stage trials
Orally delivered biologic drug to treat and prevent C. difficile infection to start recruiting for late-stage trials in Q4 2023 SEATTLE, Oct. 17, 2023 /PRNewswire/ -- Lumen Bioscience—a clinical-stage biotechnology company developing biologic drugs for highly prevalent diseases, today...Lumen Bioscience Receives Fast Track Designation from U.S. FDA for LMN-201
— Orally delivered biologic drug for treatment and prevention of C. difficile infection — LMN-201 to start pivotal trials in 2023 SEATTLE, May 17, 2023 /PRNewswire/ -- Lumen Bioscience—a clinical-stage biotechnology company developing biologic drugs for highly prevalent diseases—today...Lumen Bioscience Awarded $8.8 million from U.S. Department of Defense to Develop Fast-Acting, Intranasal Countermeasure Against Respiratory Viruses
SEATTLE, May 11, 2023 /PRNewswire/ -- Lumen Bioscience, "Lumen," a clinical-stage biotechnology company developing biologic drugs for highly prevalent diseases, today announced a new $8.8 million project funded by the U.S. Department of Defense (DOD) to develop and test a prototype...
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Lumen Bioscience
Sign Up For FreeTo access detailed company insights
Seattle-based Lumen Bioscience, Inc. has developed a new spirulina-based drug discovery, manufacturing, and delivery platform for highly prevalent diseases and disorders that have been difficult to address with conventional biopharmaceutical tools. Lumen's unique platform offers the potential to transform the biologics industry through increased sp... Read More
